Flagship explainer

What drives NURIX THERAPEUTICS, INC.’s return on equity?

ROE is five filed business factors multiplied together.

DuPont return on equity factor treeReturn on equity branches into tax burden, interest burden, operating margin, asset turnover, and the equity multiplier.Return on equity−50%Tax burden100%net income ÷ pretax incomeInterest burden92%pretax ÷ operating incomeOperating margin−340%operating income ÷ revenueAsset turnover0.12×revenue ÷ average assetsEquity multiplier1.27×average assets ÷ average equityAs of 2025-11-30 · 1 SEC filing sourceBuy Like Buffett · buylikebuffett.com
DuPont source inputs
InputValueFiscal yearSource
−$264MFY2025
Income before tax−$264MFY2025
Operating income−$286MFY2025
$84MFY2025
Ending assets$688MFY2025
Beginning assets$669MFY2024
$539MFY2025
$527MFY2024
Source: · event Nov 30, 2025 · retrieved Oct 30, 2026 · annual-row source set
Embed this chart

View the full NURIX THERAPEUTICS, INC. analysis at Buy Like Buffett